Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer

被引:5
|
作者
Bold, Krysten W. [1 ]
Toll, Benjamin A. [1 ,2 ,3 ]
Cartmel, Brenda [4 ]
Ford, Bennie B. [1 ]
Rojewski, Alana M. [2 ,3 ]
Gueorguieva, Ralitza [1 ,4 ]
O'Malley, Stephanie S. [1 ,5 ]
Fucito, Lisa M. [1 ,5 ,6 ]
机构
[1] Yale Sch Med, New Haven, CT USA
[2] Med Univ South Carolina, Charleston, SC 29425 USA
[3] Hollings Canc Ctr, Charleston, SC USA
[4] Yale Sch Publ Hlth, New Haven, CT USA
[5] Yale Canc Ctr, New Haven, CT USA
[6] Smilow Canc Hosp Yale New Haven, New Haven, CT USA
来源
JOURNAL OF SMOKING CESSATION | 2018年 / 13卷 / 04期
基金
美国国家卫生研究院;
关键词
D O I
10.1017/jsc.2017.24
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Lung cancer screening and tobacco treatment for patients at high-risk for lung cancer may greatly reduce mortality from smoking, and there is an urgent need to improve smoking cessation therapies for this population.Aims: The purpose of this study is to test the efficacy of two separate, sequential interventions to promote tobacco cessation/reduction compared to standard care in smokers considered high-risk for lung cancer.Methods: The study will recruit 276 current smokers attending a lung cancer screening clinic or considered high-risk for lung cancer based on age and smoking history across two sites. Patients first will be randomized to either standard tobacco treatment (8 weeks of nicotine patch and five individual counselling sessions) or standard tobacco treatment plus personalized gain-framed messaging. At the 8-week visit, all patients will be re-randomized to receive biomarker feedback or no biomarker feedback. Repeated assessments during treatment will be used to evaluate changes in novel biomarkers: skin carotenoids, lung function, and plasma bilirubin that will be used for biomarker feedback. We hypothesize that personalized gain-framed messages and receiving biomarker feedback related to tobacco cessation/reduction will improve quit rates and prevent relapse compared to standard care. Primary outcomes include 7-day point-prevalence abstinence verified with expired carbon monoxide at 8 weeks and mean cigarettes per day in the past week at 6 months.Conclusions: Study findings will inform the development of novel interventions for patients at risk for lung cancer to improve smoking cessation rates.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [1] Personalized Treatment for Patients With Lung Cancer
    Schuler, Martin
    Bolukbas, Servet
    Darwiche, Kaid
    Theegarten, Dirk
    Herrmann, Ken
    Stuschke, Martin
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (17): : 300 - +
  • [2] Personalized treatment of lung cancer
    Goetschke, J.
    Kahnert, K.
    Tufman, A.
    PNEUMOLOGE, 2019, 16 (02): : 69 - 75
  • [3] Personalized Treatment of Lung Cancer
    Salgia, Ravi
    Hensing, Thomas
    Campbell, Nicholas
    Salama, April K.
    Maitland, Michael
    Hoffman, Philip
    Villaflor, Victoria
    Vokes, Everett E.
    SEMINARS IN ONCOLOGY, 2011, 38 (02) : 274 - 283
  • [4] A Personalized Navigation Program to Increase Clinical Trial Participation of Lung Cancer Patients
    Ciupek, A.
    Perloff, T.
    King, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2026 - S2026
  • [5] A pilot test of a combined tobacco dependence treatment and lung cancer screening program
    Ferketich, Amy K.
    Otterson, Gregory A.
    King, Mark
    Hall, Nathan
    Browning, Kristine K.
    Wewers, Mary Ellen
    LUNG CANCER, 2012, 76 (02) : 211 - 215
  • [6] The Inform Personalized Medicine Program for High-Risk Paediatric Cancer Patients
    van Tilburg, C. M.
    Worst, B. C.
    Balasubramanian, G. P.
    Fiesel, P.
    Pfaff, E.
    Freitag, A.
    Witt, R.
    Taylor, L.
    Milde, T.
    von Deimling, A.
    Eggert, A.
    Lichter, P.
    Capper, D.
    Pfister, S. M.
    Jones, D. T. W.
    Witt, O.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S8 - S8
  • [7] A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
    Shilo, S.
    Silman, H.
    Urban, D.
    Zer, A.
    Bar-Shai, A.
    Epstein, S.
    Agbarya, A.
    Peled, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S916 - S916
  • [9] Integration of Tobacco Cessation in a Lung Cancer Screening Program
    Steliga, Matthew A.
    Franklin, Patricia L.
    Gladfelter, Anna
    Meek, Mary E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S267 - S268
  • [10] Associations between cancer diagnosis and patients' responses to an inpatient tobacco treatment intervention
    Palmer, Amanda M.
    Rojewski, Alana M.
    Nahhas, Georges J.
    Michael Cummings, K.
    Warren, Graham W.
    Toll, Benjamin A.
    CANCER MEDICINE, 2021, 10 (15): : 5329 - 5337